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Abstract Endosomal proteases have been implicated in the 
degradation of internalized regulatory peptides involved in the 
control of metabolic pathways and in the processing of 
intracellular antigens for cytolytic immune responses. Processing 
in the endocytic vesicles is regulated by changes in endosomal 
acidity due to the presence of an ATP-dependent proton pump 
which modulates protease activity, protein unfolding and 
receptor-ligand interactions. A limited number of proteases 
appear to reside in endosomes which do not contain the full 
complement of active proteases capable of completely degrading 
all internalized polypeptides. Retention of some acid hydrolases 
in endosomes is apparently related to their association with 
undefined endosomal membrane receptors. The limited number of 
proteases and the pH gradient from neutral to acidic (pH 7 to 5) 
within endosomes make possible a selective and controlled 
processing environment in comparison to lysosomes. The full 
set of endo- and exopeptidases that break down proteins to amino 
acids are active later in the pathway in lysosomes. 
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(insulin, glucagon, epidermal growth factor (EGF), invariant 
chain (Ii), antibodies and vitellogenin) and activation (lysoso- 
mal hydrolases, parathyroid hormone (PTH), protein antigens 
and toxins) of internalized proteins. The intraendosomal 
cleavage of proteins following endocytosis has been studied 
in a large number of cells, especially hepatocytes, macro- 
phages, B-lymphocytes, fibroblasts and oocytes. These studies 
have raised interesting questions regarding the extent of en- 
dosomal proteolysis in different cell types, the nature and 
specificity of endosomal proteases, the points in the endocytic 
pathway where acid hydrolases are delivered and the mechan- 
isms by which proteases are permanently retained within en- 
dosomes. Furthermore, recent studies have demonstrated that 
the cysteine protease cathepsins B and H, and the aspartic 
protease cathepsin D play a particularly important role in 
endosomal proteolysis. The present review focuses on the en- 
dosomal pathways involved in the processing of polypeptide 
hormones and internalized antigenic proteins. 
2. Proteolytic modifications of internalized proteins in 
endosomes 
1. Introduction 
Two predominant cellular systems participate in the degra- 
dation of cellular proteins: the cytoplasmic ubiquitin pathway 
and the vacuolar pathway (including mainly lysosomes and 
endosomes). The lysosomes, with their broad-specificity pro- 
teases, were considered to be organelles where complete de- 
gradation occurs. Recently, the study of endocytosis has 
broadened the view that early and late endosomes are not 
only sites of sorting and segregation, but also represent a 
biologically important processing compartment within cells. 
Recent evidence also indicates that lysosomal hydrolases are 
introduced into the endocytic pathway at an early stage so 
that partial or even complete hydrolysis of macromolecules 
may take place in prelysosomal compartments. 
Hormones, growth factors, toxins, hydrolase precursors and 
foreign antigens are cleaved by endosomal proteases. The re- 
stricted endosomal proteolysis i utilized both for inactivation 
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2.1. Early observations 
Cell-free studies with intact endosomes by Diment and 
Stahl [1] and Pease et al. [2] provided indication that endo- 
somes might be proteolytically active against internalized 
mannosylated bovine serum albumin (mannose-BSA) and in- 
sulin (Fig. 1). Subsequent investigations have implicated en- 
dosomal proteases in processing polypeptide hormones uch 
as glucagon [3-6] and PTH [7], growth factors such as EGF 
[8], plant and bacterial toxins such as ricin toxin [9,10] and 
cholera toxin [11]. The conclusion that degradation of inter- 
nalized ligands occurs or is, at least in part, initiated in en- 
docytic vesicles is based on: (i) the high recovery of internal- 
ized ligands in purified endosomes by subcellular fractionation 
studies, while little association was observed with lysosomes 
[12]; (ii) the major accumulation of internalized hormones 
[3,12] and toxins [11] induced by acidotropic agents (i.e. 
chloroquine), while effecting a minor accumulation of these 
ligands in lysosomes; (iii) the extraction from endosomes of 
polypeptide hormone fragments of insulin [13], glucagon 
[3,4,6] and EGF [8] using a reverse-phase high performance 
liquid chromatography procedure corresponding to the in 
vivo sites of hormone hydrolysis; (iv) the degradation of en- 
dosomal igands in cell-free endosomes incubated at low pH 
[1,2,4,8,14]; (v) the identification using morphological [15], 
biochemical [16] and immunological criteria [1,6,17,18] of sol- 
uble and membrane-associated endosomal hydrolases; and 
(vi) the demonstration using iodinated protein ligands and 
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small synthetic fluorogenic substrates that endosomal hydro- 
lysis is not equivalent to that found in lysosomes [19]. 
2.2. Properties of endosomal proteases 
Using isolated intact endosomes containing internalized 
hormones, growth factors and toxins facilitated the character- 
ization of the mechanisms of endosomal proteolysis [20]. The 
proteolytic activities directed against mannose-BSA, ricin A- 
chain, PTH and glucagon were maximal at pH 4-4.5 [1,4,7,9]. 
However, those directed against insulin and EGF displayed 
broad pH optima (pH 5 5.5), and were catalytically active at 
pH 7 [8,14]. Although mainly identified at low pH, endosomal 
proteolysis was detected at pH 7 if ATP, the substrate of the 
H+-ATPase, was added to the medium [1,4,9,14]. The ability 
of ATP to stimulate ndosomal proteases did not occur if the 
isotonic medium was depleted of CI-, as expected from the 
electrogenic properties of the endosomal proton pump [21]. 
The effect of ATP was also suppressed by weak bases (i.e. 
chloroquine and dansyl cadaverine), by proton ionophores 
(i.e. monensin, nigericin and valinomycin) and by inhibitors 
of the vacuolar-type H+-ATPase (i.e. N-ethylmaleimide and 
dicyclohexylcarbodiimide) [1,4,9,14]. Thus, endosomal proteo- 
lysis is functionally linked to ATP-dependent proton pump- 
mediated acidification of the endosome lumen. Inhibiting the 
dissociation of insulin and glucagon from their respective n- 
dosomal receptors reduced ligand degradation [4,14,22]. This 
indicated that ATP likely stimulated endosomal proteolysis by 
promoting endosomal acidification with subsequent ligand-re- 
ceptor complex dissociation and degradation of free luminal 
ligands by acid-optimal proteases. 
2.3. Patterns of endosomal proteolysis 
Because of the potential importance of endosomal proteo- 
lytic activities in terminating or otherwise in altering the hor- 
mone signal by the generation of biologically active degrada- 
tion products, investigations have been carried out to 
determine the extent of endosomal hydrolysis. For some li- 
gands, complete hydrolysis was observed, while for others, 
proteolysis appears to be limited (see Table 1). Large protein 
ligands, such as galactosylated-BSA or asialoorosomucoid, 
which require extensive ndo- and exopeptidase actions to 
be converted into trichloroacetic acid (TCA)-soluble material 
are not significantly degraded [19]. A single cleavage of PTH- 
(1-84) at the peptide bond F34V 35 to the bioactive fragment 
PTH-(1 34) has been identified in endosomes of rabbit alveo- 
lar macrophages, with a subsequent release of this physiolog- 
ically relevant form in the cellular medium [7]. Degradation of 
tyramine-cellobiose-labeled asialofetuin i  isolated rat hepato- 
cytes begins in endosomes and is completed in lysosomes [23]. 
Other studies have documented that EGF undergoes limited 
proteolysis at its C-terminus within endosomes of human, rat 
fibroblasts and rat hepatocytes [8]. Three forms of EGF pro- 
cessed at their C-termini appear to be generated in a sequen- 
tial fashion in endosomes: EGF-(1 52) which results from the 
removal of an arginine residue, EGF-(1M8) which results 
from the removal of a tetrapeptide W49-WS° E51-L 52 and in 
which a lysine residue exposed at the new C-terminus is re- 
moved to generate the EGF-(l~47) form. After its entry into 
lysosomes, EGF- ( I~7)  is subsequently degraded to small 
peptides and amino acids by one or more leupeptin-inhibita- 
ble proteases [8]. 
In Xenopus oocytes vitellogenin undergoes cleavage into 
large fragments within an endocytic compartment termed 
'light yolk platelets' [24]. On the other hand, the rapid and 
complete degradation to TCA-soluble products of mannose- 
BSA has been reported within macrophage ndosomes [1]. 
Within hepatic endosomes, insulin and glucagon also are to- 
tally degraded and transport o lysosomes is not required 
[4,6,13,14]. Endosomal degradation of glucagon arises from 
proteolytic modifications at the C-terminal (carboxypeptidase 
activity), internal (endopeptidase activity) and N-terminal 
(mainly tripeptidyl aminopeptidase activity) regions of the 
Table 1. The substrates of endosomal proteolytic activities and their type of processing 




















endosomal acidic complete 
insulinase (EAI) 





B-like and trypsin-like 
partial 
partial 
Y16-L17, GZa-F 24, F24-F 25 [13] 
Q3 6 4, F6_T 7, TT_S 8, D9_ylO, [6] 
Sll_K 12, L14_D 15, Q20_D21 ' 
F22_V 23, V23_Q 24, Q24_W25 ' 
W25_L 26, L26_M 27, M~7_N2S, 
NZS_T29 
F 34 V 35 [7] 
[8] 
cathepsins B and D partial ND 
ND partial ND 
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Fig. 1. The delivery and sorting of proteases and ligands into endosomes. Polypeptide hormones (left) and antigen proteins (right) are delivered 
from the cell surface into endocytic vesicles in which proteases are transported from intracellular sources uch as the Golgi apparatus. TGN, 
trans-Golgi network; Pro-c, inactive procathepsins; c, active cathepsins; Ag-II, extracellular antigens which bind to class II MHC molecules. 
hormone [3,4,6]; while endosomal insulin degradation appears 
to be largely effected by endopeptidase activity [13]. 
Endosomal proteolysis of internalized ligands regulates the 
intracellular fate of ligand and may be important both in 
terminating and in promoting intracellular signal transduc- 
tion. The endosomal processing of insulin, EGF and glucagon 
produces fragments which are unable to bind to their respec- 
tive receptors. Thus, one potential role of endosomal proteo- 
lysis of insulin and EGF may be to modulate (EGF) or ter- 
minate (insulin) receptor tyrosine kinase activation by limited 
(EGF) or complete (insulin) processing of the ligands [25]. In 
contrast, limited proteolysis of PTH-(1-84) to a smaller bioac- 
tive form PTH-(1-34) [7], and partial digestion of protein 
antigens by B-lymphocytes ( ee above) lead to the promotion 
rather than termination of signalling. This is effected by ex- 
ternalizing metabolites which serve functions (adenylate cy- 
clase activation and immune response) different from that of 
the intact molecules. Also, inhibition of cathepsins B and D or 
neutralization of the acidic endosomal pH lead to the accu- 
mulation of A-chains of diphtheria nd ricin toxins inside the 
cell and reduce toxin cytotoxicity [10,26]. Thus, the low en- 
dosomal pH and the restricted cleavages of plant and bacterial 
toxins upon delivery into endosomes appears to be critical in 
their translocation through the endosome membrane into the 
cytoplasm [10,11]. 
3. The nature of endosomal proteases 
A number of studies have reported that lysosomal enzymes 
appear to reside permanently in the endosomal compartment 
(see Table 2). These biochemical and morphological studies 
have defined the thiol-dependent cysteine protease cathepsins 
B and H, and the pepstatin A-sensitive aspartic protease ca- 
thepsin D as responsible for the majority of proteolytic activ- 
ities in endosomes [20]. Cathepsins B and D have been iden- 
tified in endosomes of rabbit alveolar macrophages by 
biosynthetic studies and affinity chromatography purification 
[1,17], in hepatic endosomes by Western blotting and cross- 
linking procedures [6,18], and in multivesicular endosomes of 
macrophages [27] and B-lymphoblastoid cells [15] by immu- 
Table 2. Properties of proteases identified in the endosomal pparatus of various cell types 
Protease Class Optimum pH Molecular Proteolytic Inactive proform eDNA References 
weight activity in endosomes cloned 
EAI metallo r 5.5 80? endopeptidase ND no [13,16] 
cysteine 
Cathepsin B cysteine 4 and 7 30 yes yes [6,15,27,28] amino- and 
carboxypepti- 
dase (pH 4) 
endopeptidase 
(pH 7) 
Cathepsin D aspartic 4 45 endopeptidase yes yes 
Cathepsin H cysteine 5 28 aminopeptidase ND yes 
Carboxypeptidase 
B-like ND ND ND carboxypeptidase ND no [8] 
Trypsin-like ND ND ND endopeptidase ND no [8] 
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nocytochemistry. The endosomal location of cathepsins B, D 
and H has been confirmed in several different cell types using 
synthetic fluorogenic substrates taken up by fluid-phase pino- 
cytosis [28]. Both cathepsins B and D are active against a wide 
variety of substrates and catalyze the endosomal degradation 
of mannose-BSA, PTH, glucagon, ricin A-chain and vitello- 
genin. Leucyl-[~-naphthyl amidase activity has also been de- 
tected in endosomes of HeLa cells [29]. 
However, other more poorly characterized endosomal pro- 
teases seem to have a more restricted substrate specificity 
(Tables 1 and 2). Thus, carboxypeptidase B-like and trypsin- 
like proteases are responsible for EGF processing within he- 
patocyte and fibroblast endosomes [8]. An endosomal acidic 
insulinase (EAI) has been partially purified using an affinity 
purification protocol [16]. EAI is a thiol endopeptidase with a 
partial metal ion requirement which differs from the pre- 
viously extensively studied 'insulin-degrading enzyme' 
[16,30,31]. EAI may be restricted to cells highly enriched in 
insulin receptors. Thus, in contrast o Fao hepatoma cells, 
Chinese hamster ovary cells transfected with the human insu- 
lin receptor were unable to degrade insulin rapidly. Further- 
more, the time course of degradation was identical to that of 
IGF-I I  and consistent with the delivery of internalized ligand 
to lysosomes [22]. 
The site of delivery of EAI, carboxypeptidase B-like and 
trypsin-like proteases into the endocytic pathway is unclear. 
Access to endosomes from the cell surface and/or by fusion of 
protease-containing vesicles directly from the Golgi apparatus 
are both possibilities. However, endosomal cathepsins B and 
D are transported to endosomes and lysosomes by the 215 
kDa cation independent mannose 6-phosphate receptor 
(M6P-R), which acts to sort cathepsin transport at the level 
of the trans-Golgi network (TGN) [32]. After their delivery to 
endosomes as an inactive proform, the low endosomal pH 
promotes dissociation of procathepsins from M6P-R. M6P- 
R returns to the TGN while the endosomal procathepsins 
mature. Alternatively, secreted precursors may be taken into 
cells by receptor-mediated process and proteolytically cleaved 
to their mature form in endosomes [33]. The removal of pro- 
peptides from newly synthesized cathepsins requires proteo- 
lytic processing to attain full activity. Endosomal maturation 
of inactive procathepsins seems pecifically to occur for only a 
few enzymes (such as procathepsins B and D), while other 
inactive proforms (such as procathepsin L) could require ly- 
sosomal delivery to undergo propeptide removal [6]. Some 
studies suggest hat cathepsin D may autoactivate and may 
also activate other cathepsins such as cathepsin B [34]. 
The mechanism(s) by which cathepsins B and D are selec- 
tively retained within the endosomal compartment are not 
clear. Selective nrichment of these cathepsins in endosomes 
may be related to their association with endosomal mem- 
branes via undefined receptors distinct from the IGF-II /  
M6P-R [32]. These membrane associations may affect both 
inactive precursor (procathepsins B and D) and active mature 
enzymes (cathepsins B and D) [6,17]. The retention agents 
could be related to the procathepsin L receptor ecently iden- 
tified within NIH 3T3 cell lines [35]. Indeed, M6P receptor- 
independent membrane association has been reported within 
endosomes (or acidic prelysosomal vesicles) for procathepsins 
D and L in macrophages [17], in HepG2 cells [36], in mouse 
fibroblasts and in KNIH cells [35], as well as in Morris hepa- 
toma 7777 cells for procathepsin C where the cation-indepen- 
dent M6P-R is absent [37]. Future studies will define the mo- 
lecular mechanisms responsible for targeting and retaining 
proteases in endosomes. 
4. Endosomal proteolysis of antigens for MHC-II presentation 
Recent studies have established a critical function for en- 
dosomal proteases in processing protein antigens to small 
peptides which are subsequently bound to major histocompat- 
ibility complex (MHC) molecules for presentation at cell sur- 
face. MHC-I molecules primarily present peptides derived 
from cytosolic antigens that are transported into the endo- 
plasmic reticulum (ER), such as viral antigens ynthesized in 
infected cells [38]. Extracellular protein antigens bind to re- 
ceptors such as immunoglobulins on B-cells and are subse- 
quently taken up by receptor-mediated ndocytosis into 
MHC-II-presenting cells [39]. Alternatively, exogenous pro- 
tein antigens may be internalized into antigen-presenting cells 
by fluid phase endocytosis. Acid-optimal proteases partially 
process these internalized proteins within the endosomal com- 
partment and generate degradation products [40]. Some de- 
gradation products which have a broad range of lengths, ty- 
pically 12-24 residues [41], bind to MHC-II molecules and are 
thereby transported to the plasma membrane (Fig. 1). A sim- 
ilar scenario applies to antibodies and antigen-antibody com- 
plexes which bind to surface Fc receptors on immune cells and 
are rapidly internalized and subsequently proteolyzed within 
endocytic vesicles [40]. The unfolding and denaturation pro- 
cesses that are needed for peptide-antigen presentation are 
induced by the low endosomal pH. The importance of endo- 
somal acidification and subsequent stimulation of acidic pro- 
teolytic activities in antigen processing and presentation is
illustrated by the facts that: (i) cells defective in endosomal 
acidification have a reduced capacity to process foreign anti- 
gens [42]; (ii) in accordance with this, agents that raise endo- 
somal pH, such as ammonium chloride and chloroquine, in- 
hibit presentation of peptides to B-cells by MHC-II [43]; and 
(iii) the covalent coupling of antigen to transferrin leads to 
internalization of the complex into B-cells via the transferrin 
receptor, followed by antigen degradation within endosomes 
[44]. 
During intracellular transport, polymorphic ~13 heterodi- 
mers of MHC-II glycoproteins associate with a type II trans- 
membrane protein termed invariant chain (Ii) [39]. In the ER, 
Ii assembles with class II molecules to form a nonameric om- 
plex composed of three c~13 dimers and an Ii trimer [45]. Ii 
displays various functions on MHC-II  molecule transport by: 
(i) facilitating folding and assembly of class II molecules; (ii) 
preventing class II molecules from binding peptides in the 
ER; and (iii) directing the nonameric (c~[~Ii)3 complexes into 
a specialized endosomal compartment via targeting informa- 
tion in the Ii cytoplasmic tail [46]. The importance of Ii in the 
sorting of class II molecules is illustrated by the fact that, in 
the absence of Ii, class II molecules aggregate and associate 
with chaperone(s) in the ER [47]. Moreover, Ii 'knockout' 
mice display deficiency in cell surface expression of class II 
molecules and protein-antigen presentation [48]. 
Endosomal targeting signals have been mapped predomi- 
nantly to a region in the N-terminal cytoplasmic domain 
that contains two dileucine-related signals and an acidic ami- 
no acid residue four or five residues N-terminal to each dileu- 
cine-related signal [46]. The precise location in the endosomal/ 
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lysosomal pathway in which Ii accumulates and is proteolyti- 
cally removed remains unclear. Morphological studies have 
shown that intracellular vesicles staining for Ii are enriched 
with endocytic markers, but also with late endosomal or ly- 
sosomal markers such as cation-independent M6P-R [49,50]. 
Once the (~I i )a  complexes arrive in endosomes, Ii is proteo- 
lytically degraded leading to the generation of N-terminal 
fragments, some of which remain transiently associated with 
class II molecules [51,52]. Complexes of ~13 with a set of 20-24 
residue Ii fragments called CLIP (class II associated invariant 
chain peptide) have been identified as intermediates in class II 
molecule maturation [53]. The CLIP segment, which likely 
binds to the ~13 binding site in a way almost identical to 
that in which antigenic peptides bind MHC-I I  molecules 
[53], is necessary for in vivo Ii activity ]54]. Proteolytic events 
also generate a 12 kDa N-terminal fragment of Ii which does 
not include the CLIP region of Ii and which remains asso- 
ciated with class II molecules for an extended period of time 
[51]. 
Thus, determination of the nature and class of endosomal 
proteases involved in antigen processing is complicated by the 
existence of two proteolytic steps: processing of Ii and that of 
antigen proteins. Moreover, it is still not known whether en- 
docytic vesicles which process Ii correspond to the compart- 
ment in which antigenic peptide loading and proteolysis oc- 
cur. Inhibitors of thiol-protease type enzymes, such as 
leupeptin, abolished egradation of Ii with subsequent inhibi- 
tion of binding of peptides to MHC-I I  and expression of 
MHC-I I  on the cell surface [43]. Characterization of the rel- 
evant proteases with a panel of inhibitors has shown that 
acidic proteases play a central role in these two processing 
steps [43] with cathepsin B-like and cathepsin D-like activities 
of major importance [55]. Processing of specific antigens (such 
as myoglobin, ovalbumin and Ii) in vitro by purified cathe- 
psins B and D generate peptides that can be presented to T- 
cells without further processing suggesting that these cysteine 
and aspartic proteolytic activities are likely the relevant pro- 
teases. 
5. Conclusion 
The endosomal system represents a cellular compartment 
located temporally and spatially between the plasma mem- 
brane and lysosomes. It is of regulatory significance in the 
selective proteolysis of polypeptide hormones and perhaps 
of major importance in peptide antigen presentation via the 
MHC class II pathway. 
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